LYMPHOPROLIFERATIVE DISORDERS

This study tests whether a stem cell transplant can cure people with serious immune system disorders. Participants, aged 4 to 69, receive healthy donor stem cells to rebuild their immune system. The goal is to see if the transplant can permanently fix the immune defect and elimin…

This early-stage study tests a new gene therapy called KLN-1010 for people with multiple myeloma that has come back or not responded to treatment. Instead of removing cells and engineering them in a lab, this therapy delivers a gene directly into the body to create cancer-fightin…

This study tests the drug pacritinib in about 100 adults with T-cell lymphoma that has returned or not responded to prior therapy. The main goal is to see how many patients' tumors shrink or disappear. Researchers will also track side effects and how long any benefits last.

This study tests a treatment called tabelecleucel for people who developed a rare, virus-linked cancer after an organ or stem cell transplant and did not improve with standard therapy. The treatment uses specially matched immune cells to fight the cancer. About 115 adults will ta…

This study tests a stem cell transplant to control peripheral T-cell lymphoma in people whose cancer has not responded to standard treatments. Participants receive a donor's stem cells after chemotherapy or antibody therapy to prepare their body. The goal is to see if this approa…

This study tests atezolizumab, a drug already approved for some cancers, in people with rare cancers that have high tumor mutational burden (TMB) or microsatellite instability (MSI). About 30 adults and children with these genetic changes will receive the drug to see if their tum…

This study tests if a stem cell transplant from a healthy donor can help people aged 4 to 75 with severe immune system disorders. Participants receive chemotherapy and then donor stem cells, followed by a hospital stay and long-term monitoring. The goal is to see if the transplan…

This study tests a drug called entrectinib in people with rare cancers that have a specific gene change (ROS1 fusion). The drug is already approved for some lung cancers, and researchers want to see if it helps shrink tumors or stop them from growing in other cancer types. About …

This study tests a drug called alectinib, already approved for some lung cancers, in people with rare cancers that have a specific genetic change called ALK. About 30 adults, teens, and children with ALK-positive cancers will receive alectinib to see if it shrinks tumors or stops…

This study tests an 8-week virtual rehab program (CaRE@Home) for adults who finished cancer treatment for breast, colorectal, head and neck cancers, or lymphoma within the last two years. The goal is to see if the program reduces disability and improves physical function, anxiety…

This study collects bone marrow, blood, and tissue samples from over 1000 people with blood cancers like myeloma and leukemia. Researchers will use advanced lab techniques to find unique markers for each cancer type. The goal is to better understand these diseases, not to test a …

This study collects tumor samples and medical information from people with lymphoma or related blood cancers who have a family history of these diseases. Researchers want to find genetic changes that may increase the risk of developing lymphoma. Participants provide blood or tiss…

This study looks at blood cancer cells from 250 patients to understand which drugs might work best for each person. Researchers will test many FDA-approved and experimental drugs on these cells in the lab. The goal is to find new treatment targets and match patients with the most…